REGENXBIO Financial Ratios
NASDAQ: RGNXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
8.07-0.02 (-0.25%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
REGENXBIO ratio analysis
REGENXBIO earned a net margin of -113.8% in FY 2025, up from -272.5% a year earlier. Return on equity reached -188.7%, meaning REGENXBIO generated -1.89 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
REGENXBIO financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | — | 11.24 | — | — | 16.59 | — | — |
| Price / sales | 4.11 | 4.62 | 8.70 | 8.68 | 2.95 | 10.94 | 40.74 | 6.93 | 95.59 | 106.75 |
| Price / book | 6.81 | 1.48 | 2.52 | 1.90 | 1.82 | 4.48 | 3.19 | 2.98 | 5.43 | 3.03 |
| Gross margin | — | 59.7% | 58.8% | 51.6% | 89.0% | 76.9% | 76.6% | 95.6% | 83.6% | 97.9% |
| Operating margin | -94.6% | -280.0% | -297.1% | -233.2% | 34.0% | -77.1% | -422.9% | 40.3% | -730.2% | -1,423.8% |
| Net margin | -113.8% | -272.5% | -292.0% | -248.7% | 27.2% | -72.0% | -268.9% | 45.7% | -704.0% | -1,372.1% |
| Free cash flow margin | -74.1% | -210.7% | -253.1% | -211.3% | 28.6% | -52.4% | -339.0% | 41.8% | -626.9% | -1,235.7% |
| Return on equity (ROE) | -188.7% | -87.5% | -84.5% | -54.3% | 16.7% | -29.5% | -21.0% | 19.6% | -40.0% | -38.9% |
| Return on assets (ROA) | -42.8% | -48.7% | -45.9% | -33.6% | 11.5% | -15.7% | -19.0% | 18.4% | -36.8% | -36.5% |
| Current ratio | 2.38 | 2.69 | 2.57 | 3.19 | 3.98 | 6.52 | 10.25 | 15.24 | 11.64 | 9.66 |
| Revenue growth | 104.5% | -7.7% | -19.9% | -76.0% | 204.3% | 338.7% | -83.9% | 2,002.4% | 126.5% | -39.5% |
| EPS growth | — | — | — | -323.4% | — | — | -194.5% | — | — | — |